Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Locally Advanced or Metastatic Breast Cancer
用户k7g3AjDeE8DM
1个月前
42
10
已完结
1. 系统已在2025-09-10 14:42:35对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1200/JCO-25-00663
文献链接: https://ascopubs.org/doi/10.1200/JCO-25-00663
其他信息:
出版社: American Society of Clinical Oncology (ASCO)
作者: Suparna Wedam; Preeti Narayan; Haley Gittleman; Joyce Cheng; Vishal Bhatnagar; Hairat Sabit; Lauren S.L. Price; Nam Atiqur Rahman; Haw-Jyh Chiu; Nikolett Biel; Tiffany Ricks; Mallorie Fiero; Shenghui Tang; Christy Osgood; William Pierce; Richard Pazdur; Paul G. Kluetz; Laleh Amiri-Kordestani
